Target intelligence / Profile preview

HLA class II histocompatibility antigen, DM alpha chain (HLA-DMA)

Target
HLA-DMA
Molecular classification
Major histocompatibility complex class II protein (non-classical), Antigen-processing chaperone, Transmembrane glycoprotein, Receptor accessory protein
01

Overview

HLA class II histocompatibility antigen, DM alpha chain (HLA-DMA) is a non-classical MHC class II alpha chain molecule that forms a heterodimer with HLA-DMB. This complex is localized primarily in intracellular vesicles of antigen-presenting cells (B lymphocytes, dendritic cells, macrophages). HLA-DM catalyzes the exchange and loading of antigenic peptides onto classical MHC class II molecules by promoting the release of the class II-associated invariant chain peptide (CLIP), shaping the repertoire of antigens presented to CD4+ T cells. HLA-DM is essential for effective adaptive immunity and modulates immune surveillance, self-tolerance, and responses to pathogens. Genetic and functional variations in HLA-DMA can influence susceptibility to autoimmune diseases and transplant outcomes, but it is not a common direct therapeutic target[1][2][3][5].

Other names
HLA-DMADMARING6D6S222EMHC class II antigen DMAReally interesting new gene 6 proteinHLADMclass II histocompatibility antigen, DM alpha chainM alpha chain
02

Mechanism of action

Enhancement of DM-catalyzed peptide exchange (experimental small molecules increase catalytic efficiency, facilitating release of peptide ligands from MHC class II)

03

Biological functions

Antigen presentationPeptide editing/loading onto MHC class IIImmune response modulationT cell activation
04

Disease associations

Autoimmune diseaseInfectionAllograft rejection/transplantationOther (e.g., rare genetic syndromes like Chediak-Higashi)
05

Safety considerations

No specific safety concerns directly attributed to targeting HLA-DMA; however, altering antigen presentation could hypothetically lead to immune dysregulation (e.g., impaired autoimmunity surveillance or altered infection response)
06

Interacting drugs

Small molecules identified in vitro that enhance HLA-DM activity

1 more in the full profile.

07

Biomarkers

No established clinical biomarkers for patient selection or efficacy monitoring specifically based on HLA-DMA

Beyond the preview

Go deeper on HLA class II histocompatibility antigen, DM alpha chain (HLA-DMA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLA class II histocompatibility antigen, DM alpha chain (HLA-DMA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call